A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China

<p> To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people living with HIV (PLWH).</p> <p>Retrospective cohort of ART-naïve PLWH initiating...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Shiyun Lv (11866220) (author)
مؤلفون آخرون:	Quanmin Li (383061) (author), Peishan Du (14037345) (author), Xuemei Ling (9683876) (author), Huolin Zhong (14043579) (author), Huijun Hou (22577690) (author), Jingliang Chen (7380431) (author), Lijuan Chen (150349) (author), Yun Lan (819172) (author), Xiaoping Tang (234051) (author), Linghua Li (7370495) (author)
منشور في:	2025
الموضوعات:	Medicine Physiology Immunology Cancer Infectious Diseases Virology Computational Biology Bictegravir/emtricitabine/tenofovir alafenamide fumarate HIV-1 efficacy drug resistance real-world
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China

مواد مشابهة